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bilities and use of Bayes’ theorem (see refer-
ences 1 and 2 for simple explanations of
Bayes’ theorem).
We noticed that healthcare professionals
in clinical genetics, when counselling indi-
viduals or couples for predictive testing for
Huntington’s disease, sometimes ignore the
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Objectives:  To assess whether healthcare professionals correctly incorporate the 
relevance of a favourable test outcome in a close relative when determining the level 
of risk for individuals at risk for Huntington’s disease.
Design and setting:  Survey of clinical geneticists and genetic counsellors from 12 
centres of clinical genetics (United Kingdom, 6; The Netherlands, 4; Italy, 1; Australia, 1) 
in May–June 2002. Participants were asked to assess risk of specific individuals in 10 
pedigrees, three of which required use of Bayes’ theorem.
cipants:  71 clinical geneticists and 41 other healthcare professionals involved in 
tic counselling.
 outcome measures:  Proportion of respondents correctly assessing risk in the 
 target pedigrees; proportion of respondents who were confident of their estimate.
lts:  50%–64% of respondents (for the three targets separately) did not include the 
rable test information and incorrectly estimated the risks as being about equal to 
rior risks; 77%–91% of these respondents were “sure” or “completely sure” that 
their estimations were correct. Twenty of the 112 respondents correctly estimated the 
risks for all three target pedigrees.
Conclusions:  Clinical geneticists and genetic counsellors frequently use prior risks in 
situations where Bayes’ theorem should be applied, leading to overestimations of the 
MJA 2005; 182: 116–118
risk for an individual.st
dis
caE imating risks of inheriting a geneticease is an important skill for health-re professionals, usually clinical
geneticists and genetic counsellors. In the
absence of genetic testing, risk estimation is a
fairly simple process. However, when genetic
testing has shown that certain relatives are
non-carriers, estimating an individual’s risk is
more complex, requiring conditional proba-
importance of favourable test outcomes in
first-degree relatives of the person being
counselled.3 To investigate this potential
problem, we conducted an anonymous sur-
vey among healthcare professionals involved
in genetic counselling prior to, and thus
unbiased by, our earlier report.3
Huntington’s disease (HD) is a hereditary,
neuropsychiatric disorder showing auto-
somal dominance, late onset, a wide range in
age at onset, and complete penetrance. The
estimated prevalence in the general popula-
tion varies between less than 1 and more
than 15 per 100 000.4 Predictive testing for
HD was introduced in 1987, and when the
genetic mutation was identified in 1993 test-
ing became technically more simple, reliable,
and available for every person at risk.5
We aimed to determine the extent to
which the principles of probability theory
and, if necessary, Bayes’ theorem1,2 were
followed when respondents estimated the
risk status of a particular individual in a
family tree.
METHODS
We designed 10 pedigrees of families with
Huntington’s disease in which one or two
individuals had recently been informed of
their mutation test outcomes. All pedigrees
contained at least one carrier of the HD
gene. (The survey with all 10 pedigrees is
available upon request.)
Original surveys were sent to contact peo-
ple in 12 centres (United Kingdom, 6; The
Netherlands, 4; Italy, 1; Australia, 1). These
people were asked to copy and distribute
the survey to staff in their centres. The
survey was conducted in May–June 2002.
Respondents were asked to estimate, for
each pedigree, the probability that a particu-
lar, clearly indicated individual “is a gene-
carrier for Huntington’s disease”, indicating
their answers on a visual analogue scale with
markers at 0, 10%, 20%, … 100%.
Respondents were also asked to indicate
how sure they were of each estimate (vary-
ing from 1 = “very unsure” to 5 = “com-
pletely sure”).
Our pedigrees included predictive test
results of individuals at 25% a priori risk or
prenatal test results on fetuses at 25% a priori
risk. Although these scenarios are less frequent
than predictive testing for individuals at 50%
risk,6 these are the situations where favourable
results may affect other relatives’ risks.
Other parameters, such as age, are impor-
tant for establishing the actual risk status of
individuals at risk for HD.7,8 For the sake of
simplicity and feasibility of the survey, we
asked our respondents to disregard these
factors. This simplification allowed any
neglect of conditional probabilities to be seen
more clearly than if age-dependent pene-
trance had also been included. Furthermore,
given the age at onset of HD, diminution of
risk in an asymptomatic at-risk individual is
not a major factor until middle life.
Six simple pedigrees and one, more com-
plicated pedigree (not presented here)
mainly served as distractions. These pedi-
grees depicted individuals for whom risk
estimation was quite straightforward with-
out making use of conditional probabilities
or Bayes’ theorem. The remaining three ped-
igrees (Box 1) were our investigation targets
(at positions #4, #7, and #9 in the sequence
of 10 pedigrees), in which risks were to beJA • Volume 182 Number 3 • 7 February 2005
R ESEARCHestimated using conditional probabilities
because of favourable genetic test results
already obtained in close relatives. Box 2
gives an example of the correct calculation.
For further information and easy calculation
of conditional probabilities, see <members.
aol.com/johnp71/bayes.html>.
Because the survey used a visual analogue
scale, we considered risk estimates for the
target pedigrees as reasonably correct if they
were within a range around the correct risk:
#4, 28%–38%; #7, 14%–19%; #9, 3%–7%.
For this anonymous survey, we neither
sought nor obtained ethical approval.
RESULTS
Seventy-one clinical geneticists (registered
or in training) and 41 other healthcare
professionals (mainly genetic counsellors)
participated voluntarily in our survey. They
worked in 12 clinical genetics centres: six in
The Netherlands, four in the United King-
dom, one in Italy, and one in Australia. The
respondents had a median of 6.5 years’
experience in genetic counselling and 2
years’ experience with HD.
Risk estimates for the simple distraction
pedigrees were 95%–99% correct. However,
risks in the target pedigrees were estimated
incorrectly as being about equal to the prior
risks by more than half of the respondents
(Box 3). Twenty respondents gave reasona-
bly correct estimates for all three targets.
The respondents’ discipline (clinical
geneticist or other) was not significantly
related to the accuracy of their target esti-
mates.
DISCUSSION
Most of our respondents appeared to be
unaware of how favourable test outcomes in
first-degree relatives may alter risks. They
did not appreciate the need to apply Bayes’
theorem in calculating conditional probabil-
ities, as has been described for X-linked
recessive disorders such as Duchenne mus-
cular dystrophy.1,2 We concluded this from
the high proportion of respondents indicat-
ing confidence in their erroneous risk calcu-
lations.
The changes in probabilities described
here are not only important for individuals
who are considering prenatal or presympto-
matic DNA testing for autosomal dominant,
hereditary, late-onset diseases such as Hunt-
ington’s disease; they also apply to heredi-
tary forms of cancer such as breast cancer
3 Summary of respondents’ accuracy in estimating risk for our target pedigrees 
(Box 1)
Pedigree #4 Pedigree #7 Pedigree #9
Respondents estimating reasonably 
correctly*
24% (26/107) 25% (28/112) 26% (28/108)
Respondents estimating incorrectly, 
as if prior risk
61% (65/107) 64% (72/112) 50% (54/108)
Respondents who used prior probability 
and were “sure” or “completely sure” 
of their estimate†
91% (59/65) 85% (58/68) 77% (39/51)
* Within range specified in Methods. † Some respondents failed to answer the question about being sure.
2 Example calculation for pedigree #9 (Box 1)
Task
Calculate probability individual IV is a carrier, denoted as P(IV carrier).
Prior probability (no test results known)
There is a 50% chance of the gene being passed to a child.
Thus, P(IV carrier)= 0.5  P(III carrier)
= 0.5  0.5  P(II carrier)
= 0.5  0.5  0.5
= 0.125 (12.5%)
Posterior probability (when two children of individual II are known to be non-carriers, 
and no other children have been tested)
P(IV carrier) = 0.5  0.5  P(II carrier)
The results of testing II’s children change P(II carrier).
P(II carrier) = 0.2
Therefore, P(IV carrier) = 0.5  0.5  0.2 = 0.05 (5%)
Status of II Non-carrier Carrier
Prior probability (A) 0.5 0.5
Probability of two non-
carrier children (B)
1.0 0.25 (0.5 for each child; independent 
events so multiply: 0.5  0.5)
Joint probability (A  B) 0.5 0.125
Posterior probability 0.5 / (0.5 + 0.125) = 0.8 0.125 / (0.5 + 0.125) = 0.2
1 Pedigrees requiring Bayes’ 
theorem for calculating risks
Squares are males, circles are females. 
Solid symbols indicate people with the disease. 
Respondents were asked to calculate the 
probabilities that individuals marked with ? are 
carriers, disregarding age at time of testing and 
age-related penetrance.
Prior probabilities (in absence of test results) are #4, 
50%; #7, 25%; #9, 12.5%. The correct probabilities 
(taking into account the known non-carrier status 
of the marked individuals) are #4, 33%; #7, 16.7%; 
#9, 5%.
See Box 2 for example calculation for pedigree #9.
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HNPCC).
Our findings raise several important ques-
tions about the adequacy of continuing edu-
cational and training programs for clinical
geneticists and genetic counsellors, and the
mathematical expertise available in clinical
genetics centres. Perhaps clinical geneticists
and genetic counsellors are easily misled by
the less complicated risk calculations, and
less ambiguous implications, after unfavour-
able test results compared with favourable
test results. Consider, for instance, the plight
of a parent at 50% risk who has two children
or fetuses tested consecutively, with the first
one being negative but the next one positive.
Such a parent’s risk status would have
changed from a prior risk of 50% to 33.3%
after the favourable first test result, but
subsequently to 100% (as an obligate car-
rier) after the adverse second test result.
Provision of full and adequate informa-
tion is one of the essential conditions to be
fulfilled in genetic counselling. If, in appro-
priate circumstances, such as in our target
scenarios, the risk is overestimated, then the
individual at risk may remain unnecessarily
anxious. Learning that the risk of carrying
the HD gene has diminished to a large
extent may reduce the anxiety about this
distressing disorder.
The perceived risk may also influence a
couple’s decisions. For example, in pedigree
#9, the risk for the father of the unborn
child has decreased from a prior risk of 25%
to 10% — a change in risk of this magnitude
is quite likely to affect the decision about
whether to have children. Furthermore,
with the risk of miscarriage after a prenatal
test at 1%–2%, parents at risk may consider
not having a prenatal test in later pregnan-
cies, knowing that favourable test results in
previous pregnancies have considerably
reduced their own risk.
It is important to remember that,
although these parents have been informed
correctly of their diminished risk based on
their children’s favourable test results, their
carrier status is still unknown. Especially in
cases of autosomal-dominant, hereditary
disorders with late onset, such as Hunting-
ton’s disease, revealing a parent’s obligate
carrier status can be very distressing. Thus,
people may choose prenatal testing to avoid
passing the disease to their children while
avoiding testing themselves, as they may not
wish to learn their own status. Of course,
they must realise and accept that an unfa-
vourable result in a child will reveal their
own status as a carrier.
There is a further potential problem if
healthcare professionals in clinical genetics
continue to use prior risks inappropriately:
the “bystander effect”. This refers to the
situation when, as more professionals fail to
take appropriate action (ie, they do not take
the favourable test results of close relatives
into account), others will be inclined to
ignore such results. Bystanders (colleagues)
can thus become the victims of “pluralistic
ignorance”.9
Our survey shows that there is a continu-
ing need for improvement in genetic risk
assessment. Our findings underline that
healthcare professionals in clinical genetics
are often using prior risks in situations
where Bayes’ theorem should be applied. We
recommend that greater attention be paid to
genetic risk calculations in continuing edu-
cation and training programs for clinical
geneticists and genetic counsellors.
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